Jared Fine

Dr. Jared Fine

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2012 in Experimental Brain Research
Verified
Journal Article
Closed access
PDF file
JFJared Fine
Jared Fine
ABA. M. Baillargeon
A. M. Baillargeon
DRD. B. Renner
D. B. Renner
NHN. S. Hoerster
N. S. Hoerster
JTJ. Tokarev
J. Tokarev
LHL. R. Hanson
L. R. Hanson

27 January 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JKJacob Kosyakovsky
Jacob Kosyakovsky
JFJared Fine
Jared Fine
WFWilliam Howard Frey
William Howard Frey
LHLeah Hanson
Leah Hanson
Identifying disease-modifying therapies for neurological diseases remains one of the greatest gaps in modern medicine. Herein, we present the rationale for intranasal (IN) delivery of deferoxamine (DFO), a high-affinity iron chelator, as a treatment for neurodegenerative and neurovascular disease with a focus on its novel mechanisms. Brain iron dyshomeostasis with iron accumulation is a known feature of brain aging and is implicated in the pathogenesis of a number of neurological diseases. A substantial body of preclinical evidence and early clinical data has demonstrated that IN DFO and other iron chelators have strong disease-modifying impacts in Alzheimer’s disease (AD), Parkinson’s disease (PD), ischemic stroke, and intracranial hemorrhage (ICH). Acting by the disease-nonspecific pathway of iron chelation, DFO targets each of these complex diseases via multifactorial mechanisms. Accumulating lines of evidence suggest further mechanisms by which IN DFO may also be beneficial in cognitive aging, multiple sclerosis, traumatic brain injury, other neurodegenerative diseases, and vascular dementia. Considering its known safety profile, targeted delivery method, robust preclinical efficacy, multiple mechanisms, and potential applicability across many neurological diseases, the case for further development of IN DFO is considerable.

1 January 2015 in Neuroscience Letters
Verified
Journal Article
Closed access
JFJared Fine
Jared Fine
DRDaniel B. Renner
Daniel B. Renner
AFAnna C. Forsberg
Anna C. Forsberg
RCRachel A. Cameron
Rachel A. Cameron
BGBenjamin T. Galick
Benjamin T. Galick
LHLeah R. Hanson
Leah R. Hanson

1 January 2020 in Neuroscience Letters
Verified
Journal Article
Closed access
JFJared Fine
Jared Fine
BSBenjamin M. Stroebel
Benjamin M. Stroebel
KFKatherine A. Faltesek
Katherine A. Faltesek
KTKaoru Terai
Kaoru Terai
LHLucas Haase
Lucas Haase
LHLeah R. Hanson
Leah R. Hanson

1 September 2017 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
JFJared Fine
Jared Fine
AFA C Forsberg
A C Forsberg
BSB M Stroebel
B M Stroebel
KFK A Faltesek
K A Faltesek
DVD R Verden
D R Verden
LHL R Hanson
L R Hanson

1 July 2014 in Brain Research
Verified
Journal Article
Closed access
JFJared Fine
Jared Fine
AFA.C. Forsberg
A.C. Forsberg
DRD.B. Renner
D.B. Renner
KFK.A. Faltesek
K.A. Faltesek
KMK.G. Mohan
K.G. Mohan
LHL.R. Hanson
L.R. Hanson